| Description | Fructosyl-peptide oxidase (FPOX-CE) (Fructosyl-peptide: oxygen oxidoreductase) is an enzyme that catalyzes the oxidation of glycopeptides. Fructosyl-peptide oxidase (FPOX-CE) shows high activity against small molecule glycated peptides, but no activity is detected against the glycated hexapeptide Fructosyl-peptide oxidase (FPOX-CE) (Fructosyl-peptide: oxygen oxidoreductase) is an enzyme that catalyzes the oxidation of glycopeptides. Fructosyl-peptide oxidase (FPOX-CE) shows high activity against small molecule glycated peptides, but no activity is detected against the glycated hexapeptide standard fVHLTPE used in the study. Fructosyl-peptide oxidase (FPOX-CE) can be used in the study of diabetes monitoring[1]... Read More | BAM(8-22), a proteolytically cleaved product of proenkephalin A, is a potent activator of Mas-related G-protein-coupled receptors (Mrgprs), MrgprC11 and hMrgprX1, and induces scratching in mice in an Mrgpr-dependent manner[1] | Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, Lixisenatide acetate is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide acetate inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide acetate can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide acetate can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis[1][2][3][4][5][6]... Read More | Mutanolysin is a biochemical reagent that can be used as a biological material or organic compound for life science related research | Neuropeptide W-23 (human) (NPW-23), the active form of Neuropeptide W, is an endogenous agonist of NPBW1 (GPR7) and NPBW2 (GPR8)[1] |